Outlook for PBE’s Biotechnology Subsectors


Nov. 20 2015, Updated 11:14 p.m. ET

Momentum and quality

The PowerShares Dynamic Biotechnology & Genome Portfolio ETF (PBE) consists of 30 biotechnology stocks. It is based on the Dynamic Biotech & Genome Intellidex Index. According to the fund’s website, the Intellidex Index “is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including: price momentum, earnings momentum, quality, management action, and value.” The ETF uses a blend of thematic and fundamental factors for investment purposes.

Article continues below advertisement

Breakdown of subsectors

Biotechnology subsectors form the largest component of PBE. 23 of the 30 holdings are from internationally recognized biotechnology companies. Pharmaceuticals and other healthcare products form the minor components of PBE. PBE currently manages a total net asset of $425 million with an expense ratio of 0.63%.

Moving averages and earnings

Amgen (AMGN), Incyte (INCY), Myriad Genetics (MYGN), Biogen Idec (BIIB), and Isis Pharmaceuticals (ISIS) are some of PBE’s top holdings. PBE’s biotechnology subsector is trading below its 100-day moving average by 3.0%, but above it 20-day and 50-day moving averages by 1.3% and 4.0%, respectively. SPY’s biotechnology sector is riding high due to strong earnings in 3Q15, beating analyst estimates by 11.1% and achieving a QoQ (quarter-over-quarter) earnings growth of 36.4%. In the next part of this series, we’ll look at the effects of adding PBE to a portfolio.


More From Market Realist

  • Open sign on a sidewalk
    Macroeconomic Analysis
    Top Reopening Stocks to Play the Shifting Market Sentiment
  • Morgan Stanley sign and stock numbers
    Macroeconomic Analysis
    Morgan Stanley's Buyback Stock Picks in 2021
  • Black Wall Street sign is sign of ethical investing
    Macroeconomic Analysis
    Ethical Investing Stocks and Funds for Your 2021 Portfolio
  • New York City skyline and Goldman Sachs logo
    Macroeconomic Analysis
    Goldman Sachs: Options Trade Picks to Play Earnings Season Volatility
  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.